Brief Reports
Copyright ©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 14, 2005; 11(42): 6701-6706
Published online Nov 14, 2005. doi: 10.3748/wjg.v11.i42.6701
Table 1 Clinical features of the studied subjects with operable HCC
CaseSexAgeHBs Ag positivityCirrhosisTumor stageTumor sizeTumorEncapsulationCapsule invasionVascular invasionPreoperative serum
ALTSG AJCC(cm)differentiationAFP (ng/mL)
1F51YesYesT2T22.4ModerateYesYesNo20
2M75YesYesT2T23.4ModerateYesYesNo25
3M52YesNoT3T210ModerateYesNoNo64
4M44YesYesT3T34WellYesYesYes69
5M44NoYesT2T22.6PoorYesYesNo73
6M53YesYesT3T28.3PoorUncertainUncertainNo100
7M65NoYesT2T24.4ModerateYesNoNo150
8F41YesYesT3T27WellYesYesNo151
9M57NoYesT3T26PoorYesYesYes152
10M46YesYesT1T11.2ModerateYesYesNo365
11M60YesYesT2T22.2PoorYesYesNo618
12M67YesYesT2T22.5ModerateYesYesNo1 057
13M48YesNoT2T24ModerateYesNoNo1 427
14M43YesNoT2T22.5ModerateYesYesNo1 500
15F31YesYesT2T22ModerateYesNoNo2 726
16M40YesNoT2T21.6ModerateNoNoNo3 338
17M35YesNoT3T28PoorYesNoNo5 505
18M42YesYesT2T23.4PoorYesYesNo12 185
19M72YesNoT3T36.5PoorYesYesNo42 837
Table 2 The average values of relative ST6Gal I activity, the relative ST6Gal I mRNA level, serum msAFP percentage in the patients with decreased (group 1) and increased (group 2) tumor ST6Gal I activity compared to that of non-tumorous tissue
Group 1: decreased ST6GalGroup 2: increased ST6GalP1
(n = 7)(n = 12)
Tumor ST6Gal I activity (mU/mg of protein)0.57 (0.47, 0.37-0.59)1.76 (1.21, 0.94-1.93)0.005
Relative tumor ST6Gal I activity (against non-tumor ST6Gal I activity)0.46 (0.42, 0.25-0.71)22.04 (1.51, 1.35-1.88)<0.001
Tumor ST6Gal I mRNA level31.78 (0.64, 0.24-1.7)1.51 (1.08, 0.68-2.6)N.S4
Serum AFP level (ng/mL)7687 (680, 246-145045)739 (161, 72-1 197)N.S.
Serum msAFP percentage (%)35 (41, 23-45)18 (13, 11-17)0.031